Global Blood Therapeutics, Inc.
GPTKB entity
Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Pfizer
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:CEO |
gptkb:Ted_W._Love
|
| gptkbp:focusesOn |
treatments for blood-based diseases
|
| gptkbp:founded |
2011
|
| gptkbp:founder |
gptkb:Ted_W._Love
|
| gptkbp:headquarters_location |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Global Blood Therapeutics, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Oxbryta
|
| gptkbp:Oxbryta_indicated_for |
sickle cell disease
|
| gptkbp:status |
subsidiary of Pfizer
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:GBT
|
| gptkbp:website |
https://www.gbt.com/
|
| gptkbp:bfsParent |
gptkb:GBT_Inc.
|
| gptkbp:bfsLayer |
7
|